First human use of an allogeneic tissue-engineered vascular graft for hemodialysis access

Journal of Vascular Surgery

Volumn 60, Issue 5, 2014, Pages 1353-1357

  Wystrychowski, Wojciech ^a   McAllister, Todd N ^b   Zagalski, Krzysztof ^a   Dusserre, Nathalie ^b   Cierpka, Lech ^a   L'Heureux, Nicolas ^b  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

^b Cytograft Tissue Engineering Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ALLOGRAFT; ARTERIOVENOUS SHUNT; ARTICLE; BALLOON DILATATION; BLOOD VESSEL GRAFT; CARDIOVASCULAR STENT; CASE REPORT; CATHETER INFECTION; FEMALE; GRAFT PATENCY; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; MECHANICAL THROMBECTOMY; MIDDLE AGED; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; RESTENOSIS; SEPSIS; THROMBECTOMY; TISSUE ENGINEERED VASCULAR GRAFT; TISSUE ENGINEERING; VERY ELDERLY; ALLOTRANSPLANTATION; BIOPROSTHESIS; BLOOD VESSEL PROSTHESIS; BLOOD VESSEL TRANSPLANTATION; CELL CULTURE; DOPPLER FLOWMETRY; FIBROBLAST; HEMODYNAMICS; IMMUNOLOGY; MALE; PROCEDURES; PROSTHESIS; RENAL REPLACEMENT THERAPY; TIME; TRANSPLANTATION; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ARTERIOVENOUS SHUNT, SURGICAL; BIOPROSTHESIS; BLOOD VESSEL PROSTHESIS; BLOOD VESSEL PROSTHESIS IMPLANTATION; CELLS, CULTURED; FEMALE; FIBROBLASTS; HEMODYNAMICS; HUMANS; MALE; MIDDLE AGED; PROSTHESIS DESIGN; RENAL DIALYSIS; TIME FACTORS; TISSUE ENGINEERING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; ULTRASONOGRAPHY, DOPPLER;

EID: 84924576993     PISSN: 07415214     EISSN: 10976809     Source Type: Journal    
DOI: 10.1016/j.jvs.2013.08.018     Document Type: Article

References (20)

1. Weinberg CB, Bell E. A blood vessel model constructed from collagen and cultured vascular cells. Science 1986;231:397-400
2. Zilla P, Fasol R, Deutsch M, Fischlein T, Minar E, Hammerle A, et al. Endothelial cell seeding of polytetrafluoroethylene vascular grafts in humans: A preliminary report. J Vasc Surg 1987;6:535-41
3. L'Heureux N, McAllister TN, de la Fuente LM. Tissue-engineered blood vessel for adult arterial revascularization. N Engl J Med 2007;357:1451-3
4. McAllister TN, Maruszewski M, Garrido SA, Wystrychowski W, Dusserre N, Marini A, et al. Effectiveness of haemodialysis access with an autologous tissue-engineered vascular graft: A multicentre cohort study. Lancet 2009;373:1440-6
5. L'Heureux N, Dusserre N, Konig G, Victor B, Keire P, Wight TN, et al. Human tissue-engineered blood vessels for adult arterial revascularization. Nat Med 2006;12:361-5
6. Dialysis Outcome Quality Initiative (KDOQI): 2006 updates. Clinical practice guidelines and recommendations. New York: National Kidney Foundation; 2006
7. Li Y, Friedman JY, O'Neal BF, Hohenboken MJ, Griffiths RI, Stryjewski ME, et al. Outcomes of Staphylococcus aureus infection in hemodialysis-dependent patients. Clin J Am Soc Nephrol 2009;4: 428-34
8. Allon M, Robbin ML. Increasing arteriovenous fistulas in hemodialysis patients: Problems and solutions. Kidney Int 2002;62:1109-24
9. Matsuura JH, Rosenthal D, Wellons ED, Castronovo CS, Fronk D. Hemodialysis graft infections treated with cryopreserved femoral vein. Cardiovasc Surg 2002;10:561-5
10. Benedetto B, Lipkowitz G, Madden R, Kurbanov A, Hull D, Miller M, et al. Use of cryopreserved cadaveric vein allograft for hemodialysis access precludes kidney transplantation because of allosensitization. J Vasc Surg 2001;34:139-42
11. Courtman DW, Errett BF, Wilson GJ. The role of crosslinking in modification of the immune response elicited against xenogenic vascular acellular matrices. J Biomed Mater Res 2001;55:576-86
12. Sato O, Okamoto H, Takagi A, Miyata T, Takayama Y. Biodegradation of glutaraldehyde-tanned human umbilical vein grafts. Surg Today 1995;25:901-5
13. Peck MK, Dusserre N, Zagalski K, Garrido SA, Wystrychowski W, Glickman MH, et al. New biological solutions for hemodialysis access. J Vasc Access 2011;12:185-92
14. Couvelard A, Leseche G, Scoazec JY, Groussard O. Human allograft vein failure: Immunohistochemical arguments supporting the involvement of an immune-mediated mechanism. Hum Pathol 1995;26: 1313-20
15. Hawkins JA, Breinholt JP, Lambert LM, Fuller TC, Profaizer T, McGough EC, et al. Class I and class II anti-HLA antibodies after implantation of cryopreserved allograft material in pediatric patients. J Thorac Cardiovasc Surg 2000;119:324-30
16. Hansbrough JF, Mozingo DW, Kealey GP, Davis M, Gidner A, Gentzkow GD. Clinical trials of a biosynthetic temporary skin replacement, Dermagraft-Transitional Covering, compared with cryopreserved human cadaver skin for temporary coverage of excised burn wounds. J Burn Care Rehabil 1997;18:43-51
17. Donohue KG, Carson P, Iriondo M, Zhou L, Saap L, Gibson K, et al. Safety and efficacy of a bilayered skin construct in full-thickness surgical wounds. J Dermatol 2005;32:626-31
18. Crapo PM, Gilbert TW, Badylak SF. An overview of tissue and whole organ decellularization processes. Biomaterials 2011;32:3233-43
19. Branchet MC, Boisnic S, Bletry O, Robert L, Charron D, Frances C. Expression of HLA class II antigens on skin fibroblasts in scleroderma. Br J Dermatol 1992;126:431-5
20. Kern A, Liu K, Mansbridge J. Modification of fibroblast gammainterferon responses by extracellular matrix. J Invest Dermatol 2001;117:112-8.